This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity

The study participants are female patients with breast cancer receiving Anthracycline based chemotherapy.

They will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin through out the study , while the other group will receive a placebo.

Full echocardiographic study including 3D echocardiography will be done to all patients before starting their chemotherapy and after 6 months.

Inclusion Criteria:

• Female patients diagnosed with histology proven breast cancer with an indication to primary systemic therapy or adjuvant regimens based on anthracyclines

Exclusion Criteria:

• Patients with impaired LV systolic function (EF below 50%)
• Patients with severe valvular heart disease
• Patients previously diagnosed with coronary artery disease
• Patients with baseline elevated liver enzymes
• Patients with prior chemotherapy or radiation therapy
• Pregnant females

Female patients diagnosed with breast cancer

Single blind